- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Lipoprotein Lipase.
Displaying page 1 of 2.
EudraCT Number: 2012-000802-32 | Sponsor Protocol Number: CLCQ908B2305 | Start Date*: 2012-10-11 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open label, long-term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004021-26 | Sponsor Protocol Number: RRK 2768 | Start Date*: 2005-10-06 |
Sponsor Name:University Hospital Birmingham | ||
Full Title: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic reg... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005075-40 | Sponsor Protocol Number: 2013-005075-40 | Start Date*: 2014-04-08 |
Sponsor Name:Research Programs' Unit, Diabetes & Obesity, University of Helsinki | ||
Full Title: The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study. | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002997-28 | Sponsor Protocol Number: ISIS304801-CS20 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Akcea Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Study of Volanesorsen (ISIS 304801) Administered Subcutaneously to Pediatric Patients with Familial Chylomicronemia Syndrome (FCS) | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002536-67 | Sponsor Protocol Number: ISIS678354-CS3 | Start Date*: 2021-04-15 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003280-95 | Sponsor Protocol Number: ISIS678354-CS13 | Start Date*: 2022-06-16 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
Medical condition: Familial Chylomicronemia Syndrome (FCS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) NO (Completed) PT (Ongoing) SK (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002192-19 | Sponsor Protocol Number: ISIS678354-CS5 | Start Date*: 2022-07-22 | ||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia | ||||||||||||||||||
Medical condition: Severe hypertryglyceridemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Ongoing) NO (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) CZ (Ongoing) FI (Ongoing) BG (Ongoing) SK (Ongoing) PT (Ongoing) PL (Ongoing) DK (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003831-31 | Sponsor Protocol Number: MS1819/18/02 | Start Date*: 2019-03-28 | |||||||||||
Sponsor Name:AzurRx | |||||||||||||
Full Title: A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe... | |||||||||||||
Medical condition: Exocrine Pancreatic Insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002750-31 | Sponsor Protocol Number: LAL-CL02 | Start Date*: 2013-05-29 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals, Inc. | |||||||||||||
Full Title: A multicenter, randomized, placebo-controlled study of SBC-102 in patients with lysosomal acid lipase deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) CZ (Completed) PL (Completed) GR (Completed) HR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000533-22 | Sponsor Protocol Number: LAL-CL08 | Start Date*: 2014-05-28 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants with Rapidly Progressive Lysosomal Acid Lipase Deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency (LALD) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004003-23 | Sponsor Protocol Number: ISIS703802 | Start Date*: 2016-09-28 | |||||||||||||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered S... | |||||||||||||||||||||||
Medical condition: Heterozygous familial hypercholesterolemia and Homozygous familial hypercholesterolemia | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-024449-65 | Sponsor Protocol Number: 159:2010/526806 | Start Date*: 2011-02-22 | |||||||||||
Sponsor Name:Västerbottens läns landsting | |||||||||||||
Full Title: Will there be lipid changes during dialysis with Citrasate as dialysate compared to conventional dialysis. | |||||||||||||
Medical condition: Chronic haemodialysis patients 18 years upwards. Patients should be in a stable condition during their chronic dialysis program (no ongoing infections or active extensive tumour with CRP above 30 m... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005083-25 | Sponsor Protocol Number: GS-US-104-0318 | Start Date*: 2005-08-12 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase IV, Randomized, Double-Blind, Placebo-Controlled Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV 1 Seronegative Healthy Adult Males | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV-1) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003680-10 | Sponsor Protocol Number: AROAPOC3-3001 | Start Date*: 2022-01-13 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome | |||||||||||||
Medical condition: Familial Chylomicronemia Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) IE (Ongoing) BE (Ongoing) ES (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004287-30 | Sponsor Protocol Number: LAL-CL06 | Start Date*: 2014-06-19 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals inc | |||||||||||||
Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency (LALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002826-22 | Sponsor Protocol Number: Tobeallocatedlater | Start Date*: 2013-10-17 |
Sponsor Name:University of Surrey | ||
Full Title: The effect of Lixisenatide on triacylglycerol and glucose metabolism in patients with type 2 diabetes | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003414-10 | Sponsor Protocol Number: NN9536-4374 | Start Date*: 2018-05-09 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes | ||||||||||||||||||
Medical condition: 1. Obesity 2. Diabetes Mellitus, Type 2 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) GR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000437-13 | Sponsor Protocol Number: R1500-HTG-20118 | Start Date*: 2022-01-07 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis | |||||||||||||
Medical condition: Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000687-30 | Sponsor Protocol Number: AROAPOC3-2001 | Start Date*: 2021-10-04 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Severe Hypertriglyceridemia | |||||||||||||
Medical condition: Severe Hypertriglyceridemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002278-30 | Sponsor Protocol Number: APH-19 | Start Date*: 2020-08-12 | |||||||||||
Sponsor Name:Amryt Pharmaceuticals DAC | |||||||||||||
Full Title: Phase III, single-arm, open-label, international, multi-centre study to evaluate the efficacy and safety of lomitapide in paediatric patients with Homozygous Familial Hypercholesterolaemia (HoFH) o... | |||||||||||||
Medical condition: Homozygous familial hypercholesterolaemia (HoFH). A rare and life-threatening inherited disorder of lipid metabolism with an estimated prevalence of 1 per 160,000 to 300,000 in the European populat... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.